Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Prophylaxis of Chemotherapy-Induced Nausea and Vomiting with Fosaprepitant and Granisetron in Pediatric Patients after Allogeneic HSCT

Karin Melanie Cabanillas Stanchi, MSc, Julia Vek, Dr. MD, Patrick Schlegel, MD, Christian M. Seitz, MD, Joachim Rupprecht, Dr. MD, Sarah Schober, Dr. MD, Sebastian Michaelis, Dr. MD, Carmen Malaval, Dr. MD, Tim Flaadt, Dr. MD, Lukas Schnaufer, Dr. MD, Manon Queudeville, Dr. MD, Judith Feucht, Dr. MD, Peter Lang, MD, Rupert Handgretinger, MD PhD, Michaela Döring, Dr. MD

Blood (2018) 132 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2018-99-112762

Published: 2018

Journal Articles

A Twenty Years Epidemiology Study of 2 nd Hematological Malignancies Post to the Initial Tumor Treatment: Report from Southern China Single Cancer Group

Siliang Chen, Zheyuan Qin, Stephen Liang, MD

Blood (2018) 132 (Supplement 1): 5903.

https://doi.org/10.1182/blood-2018-99-118481

Published: 2018

Journal Articles

Safety and Efficacy of Single-Dose Intravenous Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients with Hematooncological Malignancies after Moderate and High Emetogenic Chemotherapy

Semjon Willier, MD, Karin Melanie Cabanillas Stanchi, MSc, Martha von Have, Dr. MD, Vera Binder, Dr. MD, Franziska Blaeschke, Dr. MD, Tobias F. Feuchtinger, Prof. Dr. MD, Michaela Döring, Dr. MD

Blood (2017) 130 (Supplement 1): 3220.

https://doi.org/10.1182/blood.V130.Suppl_1.3220.3220

Published: 2017

Journal Articles

Antiemetic Prophylaxis with Granisetron and Fosaprepitant during Moderate and High Emetogenic Chemotherapy in Pediatric Patients

Michaela Döring, Dr. MD, Karin Melanie Cabanillas Stanchi, MSc, Manon Queudeville, Dr. MD, Ulrike Hartmann, Dr., Michael Ost, Dr. MD, Marie-Sarah Koch, Dr. MD, Carmen Malaval, Dr. MD, Markus Mezger, Dr. MD Dr. rer. nat., Sarah Schober, Dr. MD, Simone Weber, Dr. MD, Veit Lange, Dr. MD, Rupert Handgretinger, MD, Martin Ebinger, MD

Blood (2017) 130 (Supplement 1): 3228.

https://doi.org/10.1182/blood.V130.Suppl_1.3228.3228

Published: 2017

Journal Articles

Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 532.

https://doi.org/10.1182/blood.V130.Suppl_1.532.532

Published: 2017

Journal Articles

The Advantage of Video Assisted Education before Intrathecal Chemotherapy on Anxiety Level and Knowledge Transfer

Abdullah Bany Hamdan, BSN, RN, MSc, Walid Ballourah, MD, Sami Alshammary, MD, Sherwynn Javison, Richard Erlandez, Assem Elghazaly, MD, Musa AlHarbi, MD

Blood (2017) 130 (Supplement 1): 5619.

https://doi.org/10.1182/blood.V130.Suppl_1.5619.5619

Published: 2017

Journal Articles

A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)

Eric W Van Den Neste, MD PhD, Marc Andre, MD, Thomas Gastinne, MD, Aspasia Stamatoullas, MD, Corinne Haioun, MD PhD, Amine Belhabri, MD, Oumedaly Reman, MD, Olivier Casasnovas, MD, Herve Ghesquieres, MD PhD, Gregor Verhoef, MD PhD, Marie-José Claessen, Hélène A Poirel, Marie-Christine Copin, Romain Dubois, Peter Vandenberghe, MD PhD, Ioanna-Andrea Stoian, Anne Ségolène Cottereau, MD, Laurent Knoops, MD PhD, Franck Morschhauser

Blood (2016) 128 (22): 4160.

https://doi.org/10.1182/blood.V128.22.4160.4160

Published: 2016

Journal Articles

Challenges of Assessing Symptom Burden in Patients with Haematological Malignancies

Tatyana Ionova, PhD, Tatyana Nikitina, MD PhD

Blood (2016) 128 (22): 2369.

https://doi.org/10.1182/blood.V128.22.2369.2369

Published: 2016

Journal Articles

The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF)

Ruben Mesa, MD, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD MB, Pierre Zachee, MD PhD, Mamta Garg, MD FRCP, FRCPath, Roger Lyons, MD, Silwan Chedid, MD, Steffen Koschmieder, MD, Ciro Rinaldi, MD PhD, Jennifer Byrne, MB, ChB, PhD FRCP, FRCPath, Yasmin Hasan, MD, Francesco Passamonti, MD, Srdan Verstovsek, MD PhD, Deborah Hunter, PhD, Mark M Jones, MD, Shui He, PhD, Alex Morozov, MD PhD, Bruno Martino, MD

Blood (2014) 124 (21): 3168.

https://doi.org/10.1182/blood.V124.21.3168.3168

Published: 2014

Journal Articles

Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents

Charles L. Bennett, MD PhD, Sony Jacob, MD, Peter Georgantopoulos, MPH, MA, Judy Nichols, MSN, ACNP, Iain C Macdougall, MD

Blood (2014) 124 (21): 3516.

https://doi.org/10.1182/blood.V124.21.3516.3516

Published: 2014

Journal Articles

Cladribine for the Management of Erdheim-Chester Histiocytosis in Adults

Harsh Patel, Cary Kraft, Gary J. Schiller, MD FACP

Blood (2014) 124 (21): 5551.

https://doi.org/10.1182/blood.V124.21.5551.5551

Published: 2014

Journal Articles

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Ruben Mesa, MD, Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N. Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Shui He, PhD, Mark M Jones, MD, Shreekant Parasuraman, PhD, Jingjin Li, PhD, Isabelle Côté, MD, Dany Habr, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 709.

https://doi.org/10.1182/blood.V124.21.709.709

Published: 2014

Journal Articles

The Natural History of CSF3R -Mutated Chronic Neutrophilic Leukemia: A Mayo Clinic Series of 14 Consecutive Cases

Michelle Ann Elliott, MB, BCh, Animesh Pardanani, MBBS, PhD, Curtis A. Hanson, MD, Terra L Lasho, PhD, Christy Finke, BS, Ayalew Tefferi, MD

Blood (2014) 124 (21): 1827.

https://doi.org/10.1182/blood.V124.21.1827.1827

Published: 2014

Journal Articles

Fatal and Serious Anaphylaxis Following Peginesatide Administration

Charles L. Bennett, MD, PhD, MPP, Sony Jacob, MD, Iain C Macdougall, MD, Tom Moore, Peter Georgantopoulos, MPH, MA, Judy Nichols, Paul Yarnold, PhD, Oliver Sartor, MD, Dennis W. Raisch, PhD, MS, RPh, Ashraf Mikhail, MD, LeAnn Norris, PharmD, Samuel Kessler, BA, Jametta Magwood, BA, David Goldsmith, MB, ChB

Blood (2013) 122 (21): 5612.

https://doi.org/10.1182/blood.V122.21.5612.5612

Published: 2013

Journal Articles

Chronic Relapsing Remitting Sweet’s Syndrome- a Harbinger Of Myelodysplastic Syndrome (MDS), Single Centre Analysis Of 31 Patients

Austin G Kulasekararaj, Shahram Y Kordasti, Tanya Basu, Jon Salisbury, Anthony du Vivier, Ghulam J. Mufti, MD, PhD

Blood (2013) 122 (21): 2793.

https://doi.org/10.1182/blood.V122.21.2793.2793

Published: 2013

Journal Articles

Demographic Analysis Of 90 Polycythemia Vera Egyptian Cases : An Egyptian Reference Center Experience

Mervat Mattar, MD, Nihad Tawfik, MD, Noha Elhosseiny, MD, Mohamed Morad, MSc

Blood (2013) 122 (21): 5245.

https://doi.org/10.1182/blood.V122.21.5245.5245

Published: 2013

Journal Articles

Characteristics Associated With Transfusion Reaction Alerts At An Academic Medical Center

John Clark Henegan, MD, Mohamed Ayman Asfour, MD

Blood (2013) 122 (21): 4831.

https://doi.org/10.1182/blood.V122.21.4831.4831

Published: 2013

Journal Articles

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD, PhD, Martin Griesshammer, Prof. Dr. med., Tamás Masszi, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Pierre Zachee, MD, PhD, Fabrizio Pane, MD, Claire N Harrison, DM, FRCP, FRCPath, Shui He, PhD, Lance Leopold, MD, Jingjin Li, Ulrich Pirron, PhD, Tomasz Lawniczek, MD, PhD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4071.

https://doi.org/10.1182/blood.V122.21.4071.4071

Published: 2013

Journal Articles

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

Beata Holkova, MD, Thomas C. Shea, MD, Prithviraj Bose, MD, Mary Beth Tombes, RN, Ellen Shrader, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 1794.

https://doi.org/10.1182/blood.V120.21.1794.1794

Published: 2012

Journal Articles

How I treat enteropathy-associated T-cell lymphoma

Antonio Di Sabatino, Federico Biagi, Paolo G. Gobbi, Gino R. Corazza

Blood (2012) 119 (11): 2458–2468.

https://doi.org/10.1182/blood-2011-10-385559

Published: 2012

NARROW

Prophylaxis of Chemotherapy-Induced Nausea and Vomiting with Fosaprepitant and Granisetron in Pediatric Patients after Allogeneic HSCT

A Twenty Years Epidemiology Study of 2 nd Hematological Malignancies Post to the Initial Tumor Treatment: Report from Southern China Single Cancer Group

Safety and Efficacy of Single-Dose Intravenous Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients with Hematooncological Malignancies after Moderate and High Emetogenic Chemotherapy

Antiemetic Prophylaxis with Granisetron and Fosaprepitant during Moderate and High Emetogenic Chemotherapy in Pediatric Patients

Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies

The Advantage of Video Assisted Education before Intrathecal Chemotherapy on Anxiety Level and Knowledge Transfer

A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)

Challenges of Assessing Symptom Burden in Patients with Haematological Malignancies

The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF)

Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents

Cladribine for the Management of Erdheim-Chester Histiocytosis in Adults

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

The Natural History of CSF3R -Mutated Chronic Neutrophilic Leukemia: A Mayo Clinic Series of 14 Consecutive Cases

Fatal and Serious Anaphylaxis Following Peginesatide Administration

Chronic Relapsing Remitting Sweet’s Syndrome- a Harbinger Of Myelodysplastic Syndrome (MDS), Single Centre Analysis Of 31 Patients

Demographic Analysis Of 90 Polycythemia Vera Egyptian Cases : An Egyptian Reference Center Experience

Characteristics Associated With Transfusion Reaction Alerts At An Academic Medical Center

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

How I treat enteropathy-associated T-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only